for females ages 18-65 (full criteria)
at San Francisco, California and other locations
end: about



This study evaluated the effects of tamoxifen exposure in combination with vorinostat on viral reactivation among HIV-1 infected post-menopausal women with virologic suppression on antiretroviral therapy (ART), when compared to vorinostat alone.


The selective estrogen receptor modulator (SERM) tamoxifen may enhance the ability of the histone deacetylase inhibitor (HDACi) vorinostat to reverse HIV-1 latency. This study evaluated the safety of tamoxifen therapy combined with vorinostat and the effectiveness of this combination on latent virus reactivation in HIV-1 infected post-menopausal women with virologic suppression on antiretroviral therapy, when compared to vorinostat alone.

The study will be conducted in two steps. During Step 1, the study enrolled women with HIV into two groups. Arm A received tamoxifen daily for 38 days, plus a single dose of vorinostat on Days 35 and 38. Arm B had a 38-day observation period with no tamoxifen, plus a single dose of vorinostat on Days 35 and 38. All participants continued to take ART drugs prescribed by their doctors. ART drugs were not be provided by the study.

Study visits during Step 1 occurred at Days 0, 28, 35, 38, 45, and 65. Study visits could include physical examinations, blood collection, electrocardiograms, and adherence assessments.

During Step 2, all participants will be followed for 240 additional weeks for annual long-term safety follow-up. These visits will be conducted by phone and will collect information from participants on vital status and any new cancer diagnoses.

Step 1 has been completed and this results submission pertains to Step 1. Step 2 follow-up is ongoing.


HIV Infections, Tamoxifen, Anti-Retroviral Agents, Vorinostat, Antiretroviral drugs, Tamoxifen + Vorinostat, Vorinostat alone


You can join if…

Open to females ages 18-65

  • HIV-1 infection
  • Postmenopausal at study entry with agreement not to participate in assisted reproductive technology in the future.
  • CD4+ cell count greater than 300 cells/uL obtained within 90 days prior to study entry.
  • Continuous antiretroviral therapy (ART) for at least 2 years prior to enrollment with no known interruption in therapy for greater than 7 days within 90 days prior to study entry.
  • Plasma HIV-1 RNA level of less than 20 copies/mL obtained by Roche HIV-1 viral load assay or less than 40 copies/mL obtained by the Abbott assay, within 90 days prior to study entry.
  • Ability and willingness of potential participant to provide written informed consent.

You CAN'T join if...

  • History of venous thromboembolism.
  • History of stroke.
  • Known history of hypercoagulable state.
  • Tobacco smoking or e-cigarette use within 90 days prior to study entry.
  • History of any malignancy requiring systemic chemotherapy or systemic immunotherapy.
  • History of endometrial or breast cancer or known genetic testing with BRCA positive results indicating an increased risk for breast and ovarian cancer.
  • Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, or investigational therapy within 60 days prior to study entry.
  • Any systemic hormonal therapy defined as oral or injectable contraceptives, estrogen and combined estrogen-progesterone replacement therapy in the prior 12 months, or a hormone containing intrauterine device (IUD) within 6 months prior to study entry.
  • Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations.


  • UCSF Hiv/Aids Crs
    San Francisco California 94110 United States
  • UCLA CARE Center CRS
    Los Angeles California 90035 United States


in progress, not accepting new patients
Start Date
Completion Date
National Institute of Allergy and Infectious Diseases (NIAID)
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017
Phase 2 HIV/AIDS Research Study
Study Type
About 31 people participating
Last Updated